2Ngeow YF,Suwanjutha S,Chantarojanasriri T,et al.An asian study on the prevalence of atypical respiratory pathogens in community-acquired pneumonia.Int J Infect Dis,2005,9:144-153.
3Lepow ML,Balassanian N,Emmerich J,et al.Interrelationships of viral,mycoplasmal,and bacterial agents in uncomplicated pneumonia.Am Rev Respir Dis,1968,97:533-545.
4Lim WS,Macfarlane JT,Boswell TC,et al.Study of community acquired pneumonia aetiology(SCAPA) in adults admitted to hospital:implications for management guidelines.Thorax,2001,56:296-301.
5Niederman MS,Mandell LA,Anzueto A,et al.Guidelines for the management of adults with community-acquired pneumonia.Diagnosis,assessment of severity,antimicrobial therapy,and prevention.Am J Respir Crit Care Med,2001,163:1730-1754.
6Heffelfinger JD,Dowell SF,Jorgensen JH,et al.Management of community-acquired pneumonia in the era of pneumococcal resistance:a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group.Arch Intern Med,2000,160:1399-1408.
7Urban C, Go E, Mariano N, et al. Effect of sulbactam on infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus. J Infect Dis, 1993, 167: 448-451.
8Ang SW, Lee ST. Emergence of a multiply-resistant strain of Acinetobacter in a burns unit. Ann Acad Med Singapore, 1992, 21:660-663.
9Manikal VM, Landman D, Saurina G, et al. Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clin Infect Dis, 2000, 31: 101-106.
10Livermore DM, Williams JD.β-lactams: mode of action and mechanisms of bacterial resistance. In: Lorian V (ed). Antibiotics in laboratory medicine. 4th ed. The Williams & Wilkins Co.:Baltimore, 1996.502-578.
